Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07210125 · ClinicalTrials.gov registry record · Phase 4
Implementation and Deliver of Lenacapavir for PrEP in a Community Pharmacy Setting
A Phase 4 study of HIV, sponsored by Kelley-Ross & Associates.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 75
- Enrollment target
- 1
- Study location
NCT07210125 is a Phase 4 study of HIV that is actively recruiting participants, run by Kelley-Ross & Associates. The registered enrollment target is 75 participants, below the 440-participant average among 303 other HIV trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07210125, a Phase 4 study of HIV, is actively recruiting participants, sponsored by Kelley-Ross & Associates.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label, single center study to evaluate implementation of a pharmacist-managed delivery of L4P in a community pharmacy setting and the impact of twice-yearly vs. quarterly PrEP visits on STI rates.
Conditions Studied
Interventions
- OTHER Standard of Care (SOC)
- DRUG Lenacapavir long-acting
Study Locations (1)
Washington
- Kelley-Ross Pharmacy - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2025-09-16 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07210125
The ClinicalTrials.gov registry entry for NCT07210125 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 440-participant average among 303 other HIV trials with a reported enrollment target (83% lower). The listed sponsor is Kelley-Ross & Associates, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV appearing as the primary indexed condition, and to 2 interventions - of which Standard of Care (SOC) is the first listed.
NCT07210125 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT07210125 about?
NCT07210125 is a clinical study titled "Implementation and Deliver of Lenacapavir for PrEP in a Community Pharmacy Setting". This is an open-label, single center study to evaluate implementation of a pharmacist-managed delivery of L4P in a community pharmacy setting and the impact of twice-yearly vs. quarterly PrEP visits on STI rates.
What is the current status of trial NCT07210125?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 75 participants. The study started on 2025-09-16. Estimated completion is 2027-06-30.
What conditions does trial NCT07210125 study?
This clinical trial studies the following conditions: HIV.
What interventions are being tested in trial NCT07210125?
The interventions under investigation include: Standard of Care (SOC) (OTHER), Lenacapavir long-acting (DRUG).
Who is sponsoring clinical trial NCT07210125?
This trial is sponsored by Kelley-Ross & Associates, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07210125 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Metformin for Restoration of Immune Homeostasis in HIV+ and HIV- Individuals With a History of Injection Drug Use
RECRUITING · Phase 4
-
Integrated e-Health (Electronic Health) for HIV and Substance Use Disorders in Justice Involved Women
RECRUITING · Phase 4
-
Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject Drugs
RECRUITING · Phase 4
-
Optimizing Evidence-based HIV Prevention Targeting People Who Inject Drugs on PrEP
RECRUITING · Phase 4
-
Immediate Initiation of Antiretroviral Therapy During "Hyperacute" HIV Infection
ACTIVE NOT RECRUITING · Phase 4
-
Emtricitabine/Tenofovir Alafenamide Switch Study for Transgender Individuals for HIV Pre-exposure Prophylaxis
ACTIVE NOT RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.